key: cord-0706229-8pknnngx
authors: Duvignaud, Alexandre; Lhomme, Edouard; Onaisi, Racha; Sitta, Rémi; Gelley, Ambre; Chastang, Julie; Piroth, Lionel; Binquet, Christine; Dupouy, Julie; Makinson, Alain; Lefèvre, Benjamin; Naccache, Jean-Marc; Roussillon, Caroline; Landman, Roland; Wallet, Cédrick; Karcher, Sophie; Journot, Valérie; Nguyen, Duc; Pistone, Thierry; Bouchet, Stéphane; Lafon, Marie-Edith; Molimard, Mathieu; Thiébaut, Rodolphe; de Lamballerie, Xavier; Joseph, Jean-Philippe; Richert, Laura; Saint-Lary, Olivier; Djabarouti, Sarah; Wittkop, Linda; Anglaret, Xavier; Malvy, Denis
title: Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial (COVERAGE)
date: 2022-03-15
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2022.02.031
sha: 7963c6090ec4ce911aea6692870eba225c579889
doc_id: 706229
cord_uid: 8pknnngx

OBJECTIVES: To assess the efficacy of inhaled ciclesonide in reducing the risk of adverse outcomes in COVID-19 outpatients at risk of developing severe illness. METHODS: COVERAGE is an open-label, randomised controlled trial. Outpatients with documented COVID-19, risk factors for aggravation, symptoms <7 days and absence of criteria for hospitalisation are randomly allocated to either a control arm or one of several experimental arms, including inhaled ciclesonide. The primary efficacy endpoint is COVID-19 worsening (hospitalisation, oxygen therapy at home, or death) by Day 14. Other endpoints are adverse events, maximal follow-up score on the WHO OSCI, sustained alleviation of symptoms, cure, and RT-PCR and blood parameter evolution at Day 7. The trial’s Safety Monitoring Board reviewed the first interim analysis of the ciclesonide arm and recommended halting it for futility. The results of this analysis are reported here. RESULTS: The analysis involved 217 participants (control 107, ciclesonide 110), including 111 women and 106 men. Their median age was 63 years [Interquartile range (IQR) 59-68]. 157/217 (72.4%) had at least one comorbidity. The median time since first symptom was 4 days [IQR 3-5]. During the 28-day follow-up, 2 participants died (control 2/107 [1.9%], ciclesonide 0), 4 received oxygen therapy at home and were not hospitalized (control 2/107 [1.9%], ciclesonide 2/110 [1.8%]) and 24 were hospitalised (control 10/107 [9.3%], ciclesonide 14/110 [12.7%]). In intent-to-treat analysis of observed data, 26 participants reached the composite primary endpoint by Day14, including 12/106 (11. 3%, 95% CI 6.0 to 18.9%) in the control arm and 14/106 (13.2%; 95% CI 7.4 to 21.2%) in the ciclesonide arm. Secondary outcomes were similar for both arms. CONCLUSIONS: Our findings are consistent with the European Medicines Agency’s COVID-19 taskforce statement that there is currently insufficient evidence that inhaled corticosteroids are beneficial for people with COVID-19.

Older people and people suffering from comorbid conditions are at increased risk of adverse outcomes from COVID-19. [1] [2] [3] COVID-19 can also affect the health system by overwhelming inpatient care and oxygen supply capacities. There is therefore a need for treatments that could reduce the risk of COVID-19-related hospitalisation, oxygen indication and death. These treatments should have a good safety profile and be administered as early as possible in outpatient care. Since the rationale underpinning the treatment of COVID-19 in patients with recent symptoms is primarily antiviral, the treatment should be active against SARS-CoV-2. [4] There was no treatment for beta-coronavirus infections at the outbreak of the COVID-19

pandemic. In the hope of obtaining rapid results, the research community sought to repurpose drugs with other indications that were already in use, and therefore had a known tolerance profile. These drugs were chosen for clinical trials on the basis of preclinical arguments, including in vitro anti-SARS-CoV-2 activity and in vivo efficacy against SARS-CoV-2 in various types of animal. The number of molecules with in vitro anti-SARS-CoV-2 activity was potentially large, and clinical trials had to be adaptive to take into account the most recent data in real time and prioritise the most promising drugs. [5] [6] [7] [8] [9] In this context, we initiated a trial (COVERAGE) to study the efficacy of several repurposed drugs for early outpatient treatment of COVID-19. One of the treatments studied was inhaled ciclesonide. Ciclesonide has a favourable safety profile and anti-inflammatory properties for the respiratory tract. [10] The onset of action is faster with ciclesonide than with budesonide for improving lung function in asthmatic patients. [11] Ciclesonide also has in vitro activity against SARS-CoV-2 and MERS-CoV, with a half-maximal effective concentration of 0.55 µM in differentiated human bronchial and tracheal epithelial cells. [12] [13] [14] The COVERAGE trial allows the withdrawal of molecules for safety or futility reasons. [8, 9] Presented here are the results of the first interim futility analysis of ciclesonide. The trial participants are randomly allocated to a control arm or one of the experimental arms ongoing at the time. For each experimental arm, the trial involves two phases: a pilot phase, the objective of which is to assess the safety of the drug in outpatients with COVID-19; and an efficacy phase, the objective of which is to assess the drug's efficacy in reducing the risk of hospitalisation, need for oxygen therapy or death. The Scientific Advisory Board (SAB) can propose the opening of a new arm at any time, or the withdrawal of an ongoing arm if new external data suggest the drug is unsafe or insufficiently active against SARS-CoV-2. At the end of the pilot phase and at pre-established interim sample sizes during the efficacy phase, the Data Safety Monitoring Board (DSMB) conducts interim analyses and advises the SAB on continuation of the arm analysed. The DSMB can also advise the SAB to withdraw an arm for safety or futility reasons at any time between analyses. Fig.SA1-3 in Supplementary Appendix 1 shows all the experimental drugs included in the trial to date, and the date and reasons for withdrawing those that were halted prematurely.

The ciclesonide arm was opened on 29 December 2020. On 9 June 2021, the DSMB decided to run an interim analysis to ascertain whether the magnitude of the effect of ciclesonide observed in COVERAGE was within the range of that reported for budesonide in the PRINCIPLE trial. [15] The DSMB reviewed this interim analysis on 2 July 2021 and advised the SAB that continuing the ciclesonide arm would be futile. Based on this recommendation and blind to the results, the SAB decided to halt the ciclesonide arm on 22 July 2021. The arm was closed on 23 July 2021.

Reported here are the data from the participants randomised to the ciclesonide arm and those randomised to the control arm in the period when the ciclesonide arm was open.

Criteria for inclusion in the trial are: (i) age ≥60 years regardless of the presence of other risk factors, or ≥50 years with at least one of the following risk factors: high blood pressure, body mass index ≥30 kg/m 2 , diabetes, ischemic heart disease, heart failure, history of stroke, chronic obstructive pulmonary disease, stage ≥3 chronic kidney disease, solid or haematological malignancy diagnosed <5 years ago, immunosuppressive therapy, or HIV infection with CD4 <200/mm 3 ); (ii) COVID-19 with first symptoms ≤7 days before; (iii) positive SARS-CoV-2 nasopharyngeal RT-PCR or antigen test; (iv) no criteria for hospitalisation or acute oxygen therapy; (v) written informed consent. Exclusion criteria are: inability to understand or decide on participation; lack of health insurance; and conditions or treatment contraindicating the use of one trial drugs. For ciclesonide, the latter included chronic inhaled J o u r n a l P r e -p r o o f corticosteroid therapy, hypersensitivity to ciclesonide, history of incompletely treated pulmonary tuberculosis, pulmonary fungal infection, inability to use the inhalation chamber, and ongoing treatment with a potent CYP3A4 inhibitor.

Participants who meet all the inclusion criteria and none of the exclusion criteria are randomly assigned 1:1 to one of the trial arms, using a secure on-line system. The randomisation list has balanced blocks of fixed size and is stratified by study region. The allocated treatment is not masked from participants or investigators.

Participants allocated to the control arm receive a 10-day treatment with a combination of vitamins and trace elements (Azinc Vitality®, 2 pills per day). Participants allocated to the inhaled ciclesonide arm received a 10-day treatment with ALVESCO® 160 µg, 2 puffs twice a day using an inhalation chamber (640 µg of ciclesonide per day).

Participants are randomised at home or in an outpatient facility on day (D)0, then visited on D1, D3, D5, D7, D9, D14 and D28. D7 visits are face-to-face; other visits are by phone. Both patients and trial staff may request an additional visit at any time between scheduled visits for closer monitoring of clinical progress. Blood samples are collected from all participants at each trial centre on D0 to measure blood cell count, C-reactive protein, ferritin, lactate deshydrogenase, transaminases and creatinine. At some centres, blood samples are also collected on D7 for the same tests and a nasopharyngeal swab is collected on D7 for SARS-CoV-2 RT-PCR testing.

The primary endpoint of the pilot phase is the occurrence of grade 3-4-5 adverse events. The primary endpoint of the efficacy phase is a combination of hospitalisation, need for COVID-19-related oxygen therapy at home or death. Secondary endpoints are adverse events of any grade, maximal follow-up score on the WHO Ordinal Scale for Clinical Improvement (WHO-OSCI), sustained alleviation of symptoms (body temperature ≤37.5°C and reports of all following symptoms as minor or none, with no subsequent relapse: asthenia, headache, cough, retrosternal discomfort/pain, thoracic oppression, thoracic pain, dyspnoea, nausea, vomiting, diarrhoea, abdominal pain, anorexia, myalgia or arthralgia), cure (participant report J o u r n a l P r e -p r o o f return to normal activity with no subsequent relapse) and RT-PCR and blood parameter evolution at D7.

For the pilot phase, the sample size calculation is detailed in Appendix 2. For the efficacy phase, a sample size of 666 participants per arm was calculated as the number required to demonstrate that the proportion reaching the primary endpoint by D14 is at least 50% lower in one experimental arm than in the control arm, with the following assumptions: 7.5% reaching the primary endpoint in the control arm; 1-=95%; three interim analyses with 119, 235 and 403 participants in the arm; one-sided type-I error 6.5%, 4.5%, 2.5% and 2.5% at the first, second and third interim analyses and final analysis.

For the pilot phase, the analysis is detailed in Appendix 2. For the efficacy phase, the primary analysis compares the proportion of participants reaching the primary endpoint by Day 14 in the two arms, and is intention-to-treat (ITT) with a missing-equals-failure approach. Sensitivity analyses include: an ITT analysis of observed data, excluding participants with missing data for the main outcome; a modified ITT (mITT) analysis of observed data, additionally excluding participants wrongly included; an ITT maximum bias analysis; a per-protocol (PP) analysis of observed data. It was decided a priori that all secondary analyses would be descriptive and not subject to statistical testing.

The analyses were carried out using SAS version 9.4.

The trial protocol was approved by a French Ethics Committee (CPPIDF1-2020-ND45). Written informed consent was obtained from all participants.

During the period when the ciclesonide arm was open, 217 participants were enrolled on the ciclesonide arm or the control arm (Fig.1) . Their characteristics at baseline are detailed in Table 1 . 51% were women. The median age was 63 years (range 50-86 years), with 4 (1. (Table 1 ). The list of baseline symptoms by severity level and arm is given in Appendix 1 (Table SA1- Table 2 shows the proportion of participants who reached the primary efficacy endpoint or any of its components in each arm, and the results of the primary and sensitivity analyses. In intent-to-treat analysis of observed data, 26 participants reached the composite primary endpoint by Day14, including 12/106 (11.3%, 95% CI 6.0 to 18.9%) in the control arm and 14/106 (13.2%; 95% CI 7.4 to 21.2%) in the ciclesonide arm. The analysis package of the primary endpoint provided robust arguments to conclude that continuing the ciclesonide arm would be futile. Table 3 shows the description of the secondary outcomes.

Our data should be considered alongside others from randomised trials of inhaled corticosteroids in COVID-19 outpatients. In a phase-2 trial conducted by Song and collaborators, 61 COVID-19 adults of any age were randomised to inhaled ciclesonide or standard care (SC). The number (%) of participants reaching the primary endpoint (SARS-CoV-2 RT-PCR negativation by day 14) was 10 (32.3%) in the ciclesonide group and 1 (5.0%) in the SC group (p=0.021). [16] In the phase-2 STOIC trial, 146 adults of any age were randomised to inhaled ciclesonide or SC. The number (%) of participants reaching the primary endpoint (COVID-19-related emergency department assessment or hospitalisation) was 2 (3%) in the ciclesonide group and 11 (15%) in the SC group (p=0.009). [17] In a phase-2 trial conducted by [18] The phase-2/3 CONTAIN trial compared inhaled plus intranasal ciclesonide with a placebo in COVID-19 patients of any age with cough, dyspnea or fever. The trial was stopped early after 203 enrolling participants. The percentage of patients reaching the primary endpoint (resolution of symptoms by day 7) was 40% in the ciclesonide group and 35% in the placebo group (adjusted risk difference 5.5% (95% confidence interval −7.8% to 18.8%). The number (percentage) of participants with hospital admission by day 14 was 6 (6%) in the ciclesonide arm and 3 (3%) in the placebo arm (adjusted risk difference 2.3% (95% confidence interval −3.0% to 7.6%). [19] Finally, in the phase-3 PRINCIPLE trial, 1856 adults aged over 50 years with comorbidities, or over 65 with or without comorbidities, were randomised to inhaled budesonide or SC. The rate of hospitalisation or death was 6·8% in the budesonide group and 8.8% in the SC group. The time to recovery was 11.8 days in the budesonide group and 14.7 days in the standard care group. In Bayesian piecewise exponential analysis, the former was considered non-significant and the latter significant. [15] PRINCIPLE and COVERAGE have similar target populations and a similar hard primary endpoint (including hospitalisation and death). The difference between arms for this endpoint was nonsignificant in PRINCIPLE and led to the conclusion of futility in COVERAGE. Although the former used budesonide and the latter ciclesonide, both trials suggest that it will be difficult to prove that inhaled corticosteroid reduces the risk of clinical worsening in trials designed to include hundreds of participants, also suggesting that the efficacy of inhaled corticosteroid in reducing this risk, if any, would be small.

Limitations of our trial were: First, it was open label. It is therefore possible that some hospitalisation decisions were influenced by knowing what treatment was being provided; Second, daily symptoms were self-reported on fixed occasions. Time-to-clinical-improvement and cure are therefore to be interpreted with caution because of the risk of interval censoring; Third, we did not record information of the number of people approached for the study and the reasons for exclusion. Finally, morbidity data collected during the study do not allow for conclusions about the safety profile of inhaled ciclesonide in this population.

In conclusion, it is now considered acceptable to include repurposed drugs with good safety profiles in efficacy trials on the basis of in vitro or ex vivo arguments alone, on two conditions: first, that animal research is conducted in parallel to provide the preclinical arguments that usually precede a clinical trial; [9, 20] second, that interim analyses allow for early withdrawal of the drug if there are convincing arguments that the trial will never reach a conclusion on efficacy. This reasoning led to discontinuation of our ciclesonide arm. Our findings are J o u r n a l P r e -p r o o f consistent with the European Medicines Agency's COVID-19 taskforce (COVID-ETF) statement that there is currently insufficient evidence that inhaled corticosteroids are beneficial for people with COVID-19. [21] The COVERAGE trial is currently continuing with an inhaled interferon-β1b arm.

We thank all the persons who accepted to participate in the Trial.

The anonymized individual data and the data dictionary of the study will be made available to other researchers by the coordinating investigator, Professor Denis Malvy (denis.malvy@chubordeaux.fr) after approval of a methodologically sound proposal and the signature of a data access agreement. 

All authors declare no conflict of interest.

The trial protocol was registered in the European database EudraCT (2020-001435-27) and on clinicaltrials.gov (NCT04356495). 

The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. Tables 2 and 3 .

ITT=intention-to-treat; mITT=modified intention-to-treat; PP=per protocol;

(1) Participant on chronic inhaled corticosteroid therapy (exclusion criteria)

(2) Participants who have not been lost to follow-up before Day-9 and have not completed the 10-day treatment for reasons other than the occurrence of an adverse event.

(3) Patients lost to follow-up were excluded from the ITT analysis (4) Reasons: lost to follow-up, n=2 ; major violation of eligibility criteria, n=2 (untreated diabetes, n=1; patient requiring oxygen therapy before randomisation, n=1) (5) Reasons: lost to follow-up, n=4 ; major violation of eligibility criteria, n=2 (already on chronic inhaled corticosteroid therapy, n=1; patient requiring oxygen therapy before randomisation, n=1) (6) Patients who did not receive allocated intervention were lost to follow-up or did not complete the 10-day treatment for reasons other than the occurrence of an adverse event were excluded from PP analysis J o u r n a l P r e -p r o o f ITT, observed data  Analysed (n=106) Excluded from analysis (n=1) (3) mITT, observed data  Analysed (n=104) Excluded from analysis (n=3) (4) PP, observed data Analysed (n=91) Excluded from analysis (n=16) (6) 

Allocated to control arm (n=107)  Received allocated intervention (n=107)  Did not receive allocated intervention (n=0)

Lost to follow-up before Day 14 (n=1) Discontinued intervention (n=14) (2) ITT, missing=failure (primary analysis)  Analysed (n=110) Excluded from analysis (n=0) ITT, observed data  Analysed (n=106) Excluded from analysis (n=4) (3) mITT, observed data  Analysed (n=104) Excluded from analysis (n=6) (5) PP, observed data Analysed (n=97) Excluded from analysis (n=13) (6) Lost to follow-up before Day 14 (n=4 ) Discontinued intervention (n=10) (2) Follow-Up

Allocated to ciclesonide (n=110)  Received allocated intervention (n=109)  Did not receive allocated intervention (n=1) (1) Allocation J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f

Predictors of in-hospital COVID-19 mortality: A comprehensive systematic review and meta-analysis exploring differences by age, sex and health conditions

Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort

Development and validation of a prognostic model based on comorbidities to predict COVID-19 severity: a population-based study

An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?

Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial

Adaptive platform trials using multi-arm, multi-stage protocols: getting fast answers in pandemic settings

The Landscape of Emerging Randomized Clinical Trial Evidence for COVID-19 Disease Stages: A Systematic Review of Global Trial Registries

Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds

Research on COVID-19 therapy: Putting the cart alongside the horse

Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma

Ciclesonide is more effective than budesonide in the treatment of persistent asthma

The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells

Screening of FDA-Approved Drugs Using a MERS-CoV Clinical Isolate from South Korea Identifies Potential Therapeutic Options for COVID-19

Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Ciclesonide Inhaler Treatment for Mild-to-Moderate COVID-19: A Randomized, Open-Label, Phase 2 Trial

Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial

Efficacy of Inhaled Ciclesonide for Outpatient Treatment of Adolescents and Adults With Symptomatic COVID-19: A Randomized Clinical Trial

Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial

Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial

EMA's COVID-19 taskforce. Insufficient data on use of inhaled corticosteroids to treat COVID-19

Primary analysis, as per the trial protocol

One participant died at home at Day 5 from undocumented cause and no previous severe claims. One participant died at hospital at Day 16 from COVID19-related acute respiratory distress syndrome

Intention-to-treat, missing=failure (1) 107 13 12.1% (6.6 to 19.9) 110 18 16 .4% (10.0 to 24.6)Intention-to-treat, observed data (2) 106 12 11 .3% (6.0 to 18.9) 106 14 13 .2% (7.4 

Modified intention-to-treat, observed data (2) Oxygen therapy at home, no hospitalisation 2 2Hospitalisation 10 14 Table 3 All figures showed in this Table are from (3) Includes the three patients who received oxygen therapy at home and were never hospitalized (4)